Omnicell (NASDAQ:OMCL) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened

Omnicell, Inc. (NASDAQ:OMCL)’s share price crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $35.73 and traded as high as $51.14. Omnicell shares last traded at $50.30, with a volume of 270,997 shares.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on OMCL. UBS Group set a $53.00 price objective on shares of Omnicell in a research note on Friday, January 16th. Wells Fargo & Company lifted their price target on shares of Omnicell from $43.00 to $52.00 and gave the stock an “overweight” rating in a research note on Monday, January 5th. KeyCorp raised shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price objective for the company in a research report on Wednesday, January 7th. Benchmark raised their target price on Omnicell from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Omnicell in a research report on Thursday. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $48.57.

Omnicell Stock Down 2.0%

The company has a quick ratio of 1.21, a current ratio of 1.44 and a debt-to-equity ratio of 0.14. The firm has a market capitalization of $2.26 billion, a price-to-earnings ratio of 116.98, a P/E/G ratio of 5.36 and a beta of 0.77. The stock has a 50 day moving average of $44.06 and a 200 day moving average of $35.77.

Insider Transactions at Omnicell

In related news, EVP Corey J. Manley sold 6,106 shares of the firm’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $49.90, for a total transaction of $304,689.40. Following the transaction, the executive vice president directly owned 91,674 shares in the company, valued at $4,574,532.60. This trade represents a 6.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.52% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of OMCL. Dimensional Fund Advisors LP grew its position in shares of Omnicell by 9.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,364,068 shares of the company’s stock valued at $71,985,000 after buying an additional 197,462 shares during the last quarter. Lazard Asset Management LLC boosted its position in Omnicell by 3.8% during the 2nd quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock valued at $50,225,000 after purchasing an additional 62,733 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its stake in Omnicell by 1.3% during the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,423,604 shares of the company’s stock worth $41,854,000 after buying an additional 17,680 shares during the last quarter. Geode Capital Management LLC increased its position in Omnicell by 2.6% in the second quarter. Geode Capital Management LLC now owns 1,195,896 shares of the company’s stock worth $35,163,000 after buying an additional 30,678 shares during the period. Finally, Millennium Management LLC bought a new stake in Omnicell in the third quarter valued at $25,625,000. 97.70% of the stock is currently owned by institutional investors.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.